Trials / Recruiting
RecruitingNCT06522828
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-707 | SSGJ-707 is a bispecific antibody against human PD-1 and VEGF |
| DRUG | carboplatin | chemotherapy |
| DRUG | paclitaxel | chemotherapy |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2025-08-01
- Completion
- 2026-08-01
- First posted
- 2024-07-26
- Last updated
- 2024-10-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06522828. Inclusion in this directory is not an endorsement.